Investor Relations

Recent Event

2024 Annual Meeting of Stockholders

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has four novel and differentiated drug development programs. OLINVYK® is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.

Investor Contact Information


Trevena, Inc.
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
T: (610) 354-8840

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576